| scholarly article | Q13442814 |
| P2093 | author name string | Chaim Putterman | |
| Anna Broder | |||
| P2860 | cites work | Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort | Q83954302 |
| Real world experience with antiphospholipid antibody tests: how stable are results over time? | Q28218139 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug | Q33747286 | ||
| Pathogenic mechanisms mediating antiphospholipid syndrome | Q34404108 | ||
| Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers | Q36843689 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? | Q37721617 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus | Q38446538 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. | Q51030874 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS | Q79358178 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| antibody | Q79460 | ||
| anticoagulant | Q215118 | ||
| hydroxychloroquine | Q421094 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 30-33 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | The Journal of Rheumatology | Q7743623 |
| P1476 | title | Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus | |
| P478 | volume | 40 |
| Q92737146 | An audit of the use of hydroxychloroquine in rheumatology clinics |
| Q40130285 | Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever |
| Q38410376 | Antiphospholipid syndrome: an update |
| Q37228076 | Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study |
| Q42732278 | Commentary on "The risky business of studying prognosis". |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q50065429 | Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. |
| Q38782057 | Emerging Therapies in Antiphospholipid Syndrome |
| Q33411323 | Hematological disorders in patients with systemic lupus erythematosus |
| Q64069038 | Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study |
| Q39031764 | Hydroxychloroquine in systemic lupus erythematosus (SLE). |
| Q38934375 | Kidney disease in primary anti-phospholipid antibody syndrome |
| Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
| Q38816742 | New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity |
| Q26998188 | Obstetrical antiphospholipid syndrome: from the pathogenesis to the clinical and therapeutic implications |
| Q38425824 | Optimizing the use of existing therapies in lupus. |
| Q38794847 | Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population? |
| Q87467570 | Renal involvement in antiphospholipid syndrome |
| Q37730681 | Renal transplantation dramatically reduces IgA anti-beta-2-glycoprotein I antibodies in patients with endstage renal disease |
| Q33692770 | Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety |
| Q60108667 | Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial |
| Q51834159 | Systemic lupus erythematosus. |
| Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
| Q33443797 | Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study |
| Q35308972 | Treatment of the antiphospholipid syndrome |
| Q52654857 | Update on Antiphospholipid Syndrome: Ten Topics in 2017. |
| Q39027915 | What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies? |
Search more.